Media headlines about Zai Lab (NASDAQ:ZLAB) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zai Lab earned a coverage optimism score of 0.25 on Accern’s scale. Accern also gave news coverage about the company an impact score of 45.2004947738947 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
ZLAB has been the topic of a number of analyst reports. JPMorgan Chase & Co. initiated coverage on shares of Zai Lab in a research report on Monday, October 16th. They set a “neutral” rating and a $32.00 price objective on the stock. BidaskClub upgraded shares of Zai Lab from a “sell” rating to a “hold” rating in a research report on Wednesday, January 31st. Citigroup initiated coverage on shares of Zai Lab in a research report on Monday, October 16th. They set a “buy” rating on the stock. Finally, Leerink Swann initiated coverage on shares of Zai Lab in a research report on Monday, October 16th. They set an “outperform” rating and a $42.00 price objective on the stock.
Zai Lab (ZLAB) opened at $25.98 on Monday. Zai Lab has a 1 year low of $20.67 and a 1 year high of $35.74. The firm has a market cap of $1,280.00 and a price-to-earnings ratio of -25.47.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/05/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-zai-lab-zlab-share-price.html.
About Zai Lab
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.